These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82 related articles for article (PubMed ID: 10740407)
1. [Tissue factor and inhibitor of the blood coagulation pathway in nephrotic syndrome]. Małyszko JS; Małyszko J; Myśliwiec M Pol Arch Med Wewn; 1999 Apr; 101(4):301-5. PubMed ID: 10740407 [TBL] [Abstract][Full Text] [Related]
6. Tissue factor pathway inhibitor levels in patients with homocystinuria. Cella G; Burlina A; Sbarai A; Motta G; Girolami A; Berrettini M; Strauss W Thromb Res; 2000 Jun; 98(5):375-81. PubMed ID: 10828477 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of warfarin in the nephrotic syndrome and effect on vitamin K-dependent clotting factors. Ganeval D; Fischer AM; Barre J; Pertuiset N; Dautzenberg MD; Jungers P; Houin G Clin Nephrol; 1986 Feb; 25(2):75-80. PubMed ID: 3698349 [TBL] [Abstract][Full Text] [Related]
8. Release of extrinsic pathway inhibitor after heparin injection: increased response in cancer patients. Lindahl AK; Abildgaard U; Stokke G Thromb Res; 1990 Aug; 59(3):651-6. PubMed ID: 2237832 [No Abstract] [Full Text] [Related]
9. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Sandset PM; Larsen ML; Abildgaard U; Lindahl AK; Odegaard OR Blood Coagul Fibrinolysis; 1991 Jun; 2(3):425-33. PubMed ID: 1932528 [TBL] [Abstract][Full Text] [Related]
10. [Modification effect of the protein component of tissue thromboplastin (factor III) on its interaction with factors VII and X]. Zubairov DM; Baĭkeev RF; Byshevskiĭ ASh; Tersenov OA Biokhimiia; 1984 Jun; 49(6):971-5. PubMed ID: 6466743 [TBL] [Abstract][Full Text] [Related]
11. Plasma tissue factor and tissue factor pathway inhibitor in patients with primary glomerulonephritis. Lizakowski S; Zdrojewski Z; Jagodzinski P; Rutkowski B Scand J Urol Nephrol; 2007; 41(3):237-42. PubMed ID: 17469034 [TBL] [Abstract][Full Text] [Related]
12. Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration. Cardigan RA; McGloin H; Mackie IJ; Machin SJ; Singer M Kidney Int; 1999 Apr; 55(4):1568-74. PubMed ID: 10201024 [TBL] [Abstract][Full Text] [Related]
13. The interaction of the protein and phospholipid components of tissue thromboplastin (factor III) with the factors VII and X. Bjorklid E; Storm E; Osterud B; Prydz H Scand J Haematol; 1975 Mar; 14(1):65-70. PubMed ID: 1121648 [TBL] [Abstract][Full Text] [Related]
14. Hypercoagulability in chronic kidney disease is associated with coagulation activation but not endothelial function. Adams MJ; Irish AB; Watts GF; Oostryck R; Dogra GK Thromb Res; 2008; 123(2):374-80. PubMed ID: 18486198 [TBL] [Abstract][Full Text] [Related]
15. Recombinant human factor VIIa-induced alterations in tissue factor and thrombomodulin in patients with advanced liver cirrhosis. Van Thiel DH; Farr DE; Mindikoglu AL; Todo A; George MM J Gastroenterol Hepatol; 2005 Jun; 20(6):882-9. PubMed ID: 15946135 [TBL] [Abstract][Full Text] [Related]
19. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Broze GJ Semin Hematol; 1992 Jul; 29(3):159-69. PubMed ID: 1641662 [No Abstract] [Full Text] [Related]
20. Kinetics of the activation of bovine coagulation factor X by components of the extrinsic pathway. Kinetic behavior of two-chain factor VII in the presence and absence of tissue factor. Silverberg SA; Nemerson Y; Zur M J Biol Chem; 1977 Dec; 252(23):8481-8. PubMed ID: 925006 [No Abstract] [Full Text] [Related] [Next] [New Search]